Epidemiology of vancomycin-resistant enterococcus faecalis: A case-case-control study

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 1, 2013, Pages 49-55

  Hayakawa, Kayoko ^a   Marchaim, Dror ^a   Palla, Mohan ^a   Gudur, Uma Mahesh ^a   Pulluru, Harish ^a   Bathina, Pradeep ^a   Alshabani, Khaled ^a   Govindavarjhulla, Aditya ^a   Mallad, Ashwini ^a   Abbadi, Deepika Reddy ^a   Chowdary, Deepti ^a   Kakarlapudi, Hari ^a   Guddati, Harish ^a   Das, Manoj ^a   Kannekanti, Naveen ^a   Vemuri, Praveen ^a   Doddamani, Rajiv ^a   Mundra, Venkat Ram Rakesh ^a   Guddeti, Raviteja Reddy ^a   Policherla, Rohan ^a   Bai, Sarika ^a   Lohithaswa, Sharan ^a   Shashidharan, Shiva Prasad ^a   Chidurala, Sowmya ^a   Diviti, Sreelatha ^a   Sukayogula, Krishna ^a   Joseph, Melwin ^a   Pogue, Jason M ^b   Lephart, Paul R ^b   Martin, Emily T ^c   Rybak, Michael J ^a,c   Kaye, Keith S ^a   more..

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DETROIT MEDICAL CENTER   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CARBAPENEM; CEFAZOLIN; CEFEPIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; GENTAMICIN; LINEZOLID; MACROLIDE; METRONIDAZOLE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STEROID; STREPTOMYCIN; SULTAMICILLIN; TETRACYCLINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; CANCER CHEMOTHERAPY; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEMENTIA; DIABETES MELLITUS; ENTEROCOCCAL INFECTION; FEMALE; HOSPITAL ADMISSION; HUMAN; INFECTION PREVENTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PEPTIC ULCER; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SKIN ULCER; UNITED STATES; VANCOMYCIN RESISTANT ENTEROCOCCUS; VANCOMYCIN RESISTANT ENTEROCOCCUS FECALIS; VANCOMYCIN RESISTANT ENTEROCOCCUS FECALIS INFECTION; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CATHETERS, INDWELLING; CEPHALOSPORINS; COHORT STUDIES; COMORBIDITY; DIABETES MELLITUS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS FAECALIS; FEMALE; FLUOROQUINOLONES; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MICHIGAN; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RISK FACTORS; VANCOMYCIN RESISTANCE;

EID: 84872032139     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01271-12     Document Type: Article

References (25)

1. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK. 2008. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect. Control Hosp. Epidemiol. 29:996-1011.
2. Carmeli Y, Eliopoulos G, Mozaffari E, Samore M. 2002. Health and economic outcomes of vancomycin-resistant enterococci. Arch. Intern. Med. 162:2223-2228.
3. Hayakawa K, Marchaim D, Vidaillac C, Lephart P, Pogue JM, Sunkara B, Kotra H, Hasan A, Shango M, Yerramalla Y, Osunlana AM, Chopra T, Dhar S, Salimnia H, Rybak MJ, Kaye KS. 2011. Growing prevalence of vancomycin-resistant Enterococcus faecalis in the region with the highest prevalence of vancomycin-resistant Staphylococcus aureus. Infect. Control Hosp. Epidemiol. 32:922-924.
4. Flannery EL, Wang L, Zollner S, Foxman B, Mobley HL, Mody L. 2011. Wounds, functional disability, and indwelling devices are associated with cocolonization by methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci in southeast Michigan. Clin. Infect. Dis. 53:1215-1222.
5. Perichon B, Courvalin P. 2009. VanA-type vancomycin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53:4580-4587.
6. Centers for Disease Control and Prevention. 2012. CDC reminds clinical laboratories and healthcare infection preventionists of their role in the search and containment of vancomycin-resistant Staphylococcus aureus (VRSA). Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/HAI/ settings/lab/vrsa-lab-search-containment.html.
7. Sievert DM, Rudrik JT, Patel JB, McDonald LC, Wilkins MJ, Hageman JC. 2008. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin. Infect. Dis. 46:668-674.
8. Zhu W, Murray PR, Huskins WC, Jernigan JA, McDonald LC, Clark NC, Anderson KF, McDougal LK, Hageman JC, Olsen-Rasmussen M, Frace M, Alangaden GJ, Chenoweth C, Zervos MJ, Robinson-Dunn B, Schreckenberger PC, Reller LB, Rudrik JT, Patel JB. 2010. Dissemination of an enterococcus Inc18-like vanA plasmid associated with vancomycin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 54:4314-4320.
9. Reyes K, Malik R, Moore C, Donabedian S, Perri M, Johnson L, Zervos M. 2010. Evaluation of risk factors for coinfection or cocolonization with vancomycin-resistant enterococcus and methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 48:628-630.
10. Cetinkaya Y, Falk P, Mayhall CG. 2000. Vancomycin-resistant enterococci. Clin. Microbiol. Rev. 13:686-707.
11. Charlson ME, Pompei P, Ales KL, MacKenzie CR. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40:373-383.
12. Bion JF, Edlin SA, Ramsay G, McCabe S, Ledingham IM. 1985. Validation of a prognostic score in critically ill patients undergoing transport. Br. Med. J. (Clin. Res. Ed.) 291:432-434.
13. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. 1963. Studies of illness in the aged. The index of Adl: a standardized measure of biological and psychosocial function. JAMA 185:914-919.
14. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing; 19th informational supplement. Approved standard M100-S19. Clinical and Laboratory Standards Institute, Wayne, PA.
15. Kaye KS, Harris AD, Samore M, Carmeli Y. 2005. The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect. Control Hosp. Epidemiol. 26:346-351.
16. Carmeli Y, Eliopoulos GM, Samore MH. 2002. Antecedent treatment with different antibiotic agents as a risk factor for vancomycin-resistant Enterococcus. Emerg. Infect. Dis. 8:802-807.
17. Chavers LS, Moser SA, Funkhouser E, Benjamin WH, Jr, Chavers P, Stamm AM, Waites KB. 2003. Association between antecedent intravenous antimicrobial exposure and isolation of vancomycin-resistant enterococci. Microb. Drug Resist. 9(Suppl 1):S69-S77.
18. Hayakawa K, Marchaim D, Martin ET, Tiwari N, Yousuf A, Sunkara B, Pulluru H, Kotra H, Hasan A, Bheemreddy S, Sheth P, Lee D, Kamatam S, Bathina P, Nanjireddy P, Chalana IK, Patel S, Kumar S, Vahia A, Ku K, Yee V, Swan J, Pogue JM, Lephart PR, Rybak MJ, Kaye KS. 2012. Comparison of the clinical characteristics and outcomes associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant E. faecium bacteremia. Antimicrob. Agents Chemother. 56:2452-2458.
19. Michigan Department of Community Health. 2011. The impact of diabetes in Michigan. The Diabetes Burden Report and the Michigan Diabetes Action plan 2011-2014. Michigan Department of Community Health, Lansing, MI. http://www.michigan.gov/documents/mdch/2011-Impact-of-Diabetes-365234-7.pdf.
20. Hayakawa K, Marchaim D, Lephart P, Pogue JM, Sunkara B, Moshos JA, Jagadeesh KK, Kotra H, Hasan A, Suhrawardy U, Osunlana AM, Swan J, Patel S, Levine M, Yee V, Ahmad F, Reddy SML, Ku K, Kumar S, Yerramalla Y, Tiwari N, Mustapha M, Martin ET, Rybak MJ, Kaye KS. 2011. Risk factors for co-colonization of vancomycin-resistant Enterococcus faecalis and methicillin-resistant Staphylococcus aureus (MRSA): a multivariate analysis, abstr K-221. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL.
21. Donskey CJ, Chowdhry TK, Hecker MT, Hoyen CK, Hanrahan JA, Hujer AM, Hutton-Thomas RA, Whalen CC, Bonomo RA, Rice LB. 2000. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N. Engl. J. Med. 343:1925-1932.
22. Pultz NJ, Stiefel U, Subramanyan S, Helfand MS, Donskey CJ. 2005. Mechanisms by which anaerobic microbiota inhibit the establishment in mice of intestinal colonization by vancomycin-resistant Enterococcus. J. Infect. Dis. 191:949-956.
23. Carmeli Y, Samore MH, Huskins C. 1999. The association between antecedent vancomycin treatment and hospital-acquired vancomycin-resistant enterococci: a meta-analysis. Arch. Intern. Med. 159:2461-2468.
24. Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. 2007. Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn. Microbiol. Infect. Dis. 58:163-170.
25. Furtado GH, Mendes RE, Pignatari AC, Wey SB, Medeiros EA. 2006. Risk factors for vancomycin-resistant Enterococcus faecalis bacteremia in hospitalized patients: an analysis of two case-control studies. Am. J. Infect. Control 34:447-451